Streptococcus pneumoniae is an important infectious agent of humans who are at the extremes of age or who are immunocompromised. It is responsible for invasive diseases like pneumonia, sepsis, and meningitis, as well as less severe but highly prevalent infections such as sinusitis and otitis media. Although capsular polysaccharides from S. pneumoniae have long been considered effective immunogens against pneumococcal infection, pneumococcal proteins are thought to form the basis of novel vaccines. To identify novel pneumococcal proteins that are immunogenic in humans we screened a genomic DNA expression library of S. pneumoniae using human convalescentphase serum. Twenty-three clones encoding pneumococcal polypeptides were identified which had been immunogenic to the host during invasive pneumococcal disease or prior colonization (10) . The sequences of the inserts of clones SP-21 and SP-74 were found to be highly homologous to a putative gene from the pneumococcal genome (contig 3836, nucleotides [nt] 140,383 to 136,542) published by The Institute for Genomic Research (http://www.tigr.org). The sequence of the complete gene from S. pneumoniae strain 3.B (clinical isolate, serotype 1) was analyzed and deposited in GenBank (of the National Center for Biotechnology Information) (see below). The gene was homologous to the 3Ј region of the Bacillus sp. gene encoding alkaline amylopullulanase (apuA), encoding the site with pullulanase activity (5) . Therefore, the pneumococcal gene (3,864 nt) was designated spuA (for S. pneumoniae pullulanase A). Southern blot analysis demonstrated that spuA is a single-copy gene (data not shown), and comparison with the pneumococcal genome (http://www.tigr.org) indicates that the mRNA is monocistronic. spuA encoded a protein of 1,287 amino acid residues (Fig. 1) , with a predicted molecular mass of 143,317 Da. The calculated molecular mass correlates with the molecular mass of the main protein band determined by Western blot analysis (ϳ140 kDa) using a specific polyclonal rabbit serum raised against the N-terminal fragment (amino acids [aa] 118 to 542) of SpuA. In addition, Western blot analysis demonstrated the continuous presence of SpuA during all growth phases (Fig. 2) .
For prediction of protein localization and motif identifica- Functional analysis was performed by electrophoresis of pneumococcal extract in native 6% polyacrylamide gels at 4°C. For analysis of pullulanase activity, gels containing 0.15% Red-pullulan (Gamma Chemie, Munich, Germany) were incubated in buffer A (0.1 M NaAc, 1 mM dithiotreitol [pH 6.0]) for 3 h at 37°C. For analysis of ␣-amylase activity, gels containing 1% soluble starch were stained with I 2 and Lugol's iodine solution as described by Brooker and McCarthy (3) and Satoh et al. (7), respectively. Functional analysis confirmed the results from the deduced amino acid analysis and showed that a protein with pullulanase activity corresponded to a protein recognized by anti-SpuA (Fig. 3) . Immunoblotting of the supernatant revealed a very weak but visible band as well. As we did not solubilize the peptidoglycan, the amount of soluble SpuA is probably primarily due to autolysis of pneumococci. No corresponding ␣-amylase activity could be detected in the pullulanase-containing extracts (data not shown). However, it cannot be completely ruled out that SpuA contains such activity as, e.g., properties of amylolytic enzymes vary and can be linked to environmental circumstances.
The deduced amino acid sequence of spuA revealed the presence of a fibronectin type III repeat signature, two 18-amino-acid repeats, and several potential O glycosylation sites, whose functions in SpuA are presently unknown (Fig. 1) . Although no clear signal sequence was present, the LPXTG motif at the carboxy terminus ( Fig. 1) represents a typical sequence of gram-positive bacteria, indicating that the protein is attached to the cell wall (4, 6, 8) . The LPXTG motif was preceded by a typical proline-rich segment, thought to span the cell wall, and was followed by a hydrophobic transmembrane domain with several positively charged amino acids at its tail ( Fig. 1) . Immunocytometric analysis and immunofluorescence microscopy with anti-SpuA confirmed the surface localization of SpuA (data not shown). Considering the cellular localization of SpuA, SpuA might play a role in colonization and may solubilize mucus or affect exposition of host glycoconjugates for the pneumococcus by its ␣-1,6-glucanohydrolase activity. On the other hand, SpuA might contribute to virulence or survival of pneumococci in the host by scavenging potential carbon sources.
Western blot analysis with native extracts from 41 pneumococcal strains of 17 distinct serotypes with anti-SpuA showed that SpuA was recognized in all extracts, indicating that SpuA is serologically highly conserved. Western blot analysis using native extracts of Escherichia coli, Klebsiella oxytoca, Staphylococcus aureus, Moraxella catarrhalis, Bacillus subtilis, Enterococcus faecalis, and Streptococcus bovis showed no immunoreactive band (data not shown).
DNA sequence analysis of the 5Ј end of the spuA genes of 25 distinct pneumococcal strains representing 12 serotypes demonstrated limited variation. However, one 75-bp stretch differed among pneumococcal strains. Based upon the presence of all nucleotides and absence of 21 or 66 nucleotides the strains could be divided into three sequence types (Table 1 and Fig. 4 ). The differences include the missense of 7 or 22 amino acids, with an overlap of 2 amino acids (Fig. 1) . The pneumococcal strains of serotypes 1 (n ϭ 7) and 19F (n ϭ 2) are distributed among the three and among two spuA sequence types, respectively. In contrast, the strains of serotypes 6B (n ϭ 2), 7F (n ϭ 3), and 14 (n ϭ 3) each group within one sequence type. In addition, the 5Ј spuA gene fragments of the serotype 4 pneumococcal strain and the serotype 4 type strain used for genome sequencing (http://www.tigr.org) were identical. Furthermore, the 5Ј spuA sequence of strain D39 and its unencapsulated derivative, R6x, were identical.
The four regions forming the catalytic domain of amylolytic enzymes, like SpuA, are strongly conserved and therefore highly homologous between microorganisms and mammals. In that respect this region of SpuA is not suitable for vaccine development. In contrast, the N-terminal half of SpuA shows interesting characteristics, as this region is immunogenic, located at the surface of the pneumococcus, and species specific. Furthermore, the 5Ј region of spuA is highly conserved, except for a 75-bp region, and SpuA is present in all investigated pneumococcal strains. Inactivation of SpuA and virulence studies will enable us to understand its role in the pathogenicity of the pneumococcus.
Nucleotide sequence accession number. The sequence of the complete spuA gene for S. pneumoniae strain 3.B was deposited in GenBank under accession number AF217414.
